Abstract
Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.
Highlights
Unlike the more common serous ovarian cancers, ovarian clear cell carcinoma (OCCC) is more frequently resistant to conventional platinum/taxane chemotherapy, which worsens its prognosis [1,2].a need exists for subtype specific therapies
Ovarian clear cell carcinoma (OCCC), akin to a type I ovarian cancer [6], has a unique morphology characterized by glycogen containing clear cells and “hobnail” cells (Figure 2B)
While the initial response to platinum/taxane chemotherapy in serous carcinomas approaches 80%, OCCC are in most cases chemoresistant [1,2]
Summary
Munmun Rahman 1, Kentaro Nakayama 1,*, Tomoka Ishibashi 1, Masako Ishikawa 1, Mohammed Tanjimur Rahman 1, Hiroshi Katagiri 1, Atsuko Katagiri 1, Kouji Iida 1, Yoshihiro Kikuchi 2 and Kohji Miyazaki 1. Received: 17 February 2013; in revised form: March 2013 / Accepted: March 2013 /
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
